Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Pfizer Inc.
Pfizer Inc. News
Pfizer Inc. Quantitative Score
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer Inc. Earnings & Revenue
Pfizer Inc. Financials
Table Compare
Compare PFE metrics with: | |||
---|---|---|---|
Earnings & Growth | PFE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | PFE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | PFE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | PFE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Pfizer Inc. Income
Pfizer Inc. Balance Sheet
Pfizer Inc. Cash Flow
Pfizer Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Buy |
Return on Equity | Strong Buy |
Return on Assets | Strong Buy |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Neutral |
Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Pfizer Inc. Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 1.6800 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-12-02 | 0.42 | Quarterly |
2024-09-03 | 0.42 | Quarterly |
2024-06-14 | 0.42 | Quarterly |
2024-03-01 | 0.42 | Quarterly |
2023-12-04 | 0.41 | Quarterly |
Pfizer Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Pfizer Inc. Executives
Name | Role |
---|---|
Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board & Chief Executive Officer |
Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and President of Research & Development |
Mr. Douglas M. Lankler | Executive Vice President & General Counsel |
Mr. David M. Denton | Chief Financial Officer & Executive Vice President |
Mr. Andreas J. Panayiotou | Global Chief Marketing Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board & Chief Executive Officer | 1962 | 4.05M | |
Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and President of Research & Development | 1958 | 2.41M | |
Mr. Douglas M. Lankler | Executive Vice President & General Counsel | Male | 1966 | 1.76M |
Mr. David M. Denton | Chief Financial Officer & Executive Vice President | Male | 1965 | 1.75M |
Mr. Andreas J. Panayiotou | Global Chief Marketing Officer | Male | -- |
Pfizer Inc. Insider Trades
Date | 31 Oct |
Name | JOHNSON RADY A |
Role | Executive Vice President |
Transaction | Acquired |
Type | A-Award |
Shares | 7 |
Date | 31 Oct |
Name | BOURLA ALBERT |
Role | Chairman & CEO |
Transaction | Acquired |
Type | A-Award |
Shares | 19 |
Date | 30 Oct |
Name | Gottlieb Scott |
Role | Director |
Transaction | Acquired |
Type | P-Purchase |
Shares | 1000 |
Date | 15 Oct |
Name | JOHNSON RADY A |
Role | Executive Vice President |
Transaction | Acquired |
Type | A-Award |
Shares | 6 |
Date | 15 Oct |
Name | BOURLA ALBERT |
Role | Chairman & CEO |
Transaction | Acquired |
Type | A-Award |
Shares | 18 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
31 Oct | JOHNSON RADY A | Executive Vice President | Acquired | A-Award | 7 |
31 Oct | BOURLA ALBERT | Chairman & CEO | Acquired | A-Award | 19 |
30 Oct | Gottlieb Scott | Director | Acquired | P-Purchase | 1000 |
15 Oct | JOHNSON RADY A | Executive Vice President | Acquired | A-Award | 6 |
15 Oct | BOURLA ALBERT | Chairman & CEO | Acquired | A-Award | 18 |